RT Journal Article
T1 Assessment of Procalcitonin as a Diagnostic and Prognostic Marker in Patients with Solid Tumors and Febrile Neutropenia
A1 Jimeno, Antonio
A1 García-Velasco, Adelaida
A1 del Val, Olga
A1 González-Billalabeitia, Enrique
A1 Hernando, Susana
A1 Hernández, Rosario
A1 Sánchez-Muñoz, Alfonso
A1 López-Martın, Ana
A1 Durán, Ignacio
A1 Robles, Luis
A1 Corté-Funes, Hernán
A1 Paz-Ares, Luis
K1 Cáncer - Diagnóstico
AB Cancer patients with fever and neutropenia currently are assessedon clinical grounds only. The current study prospectively evaluated the efficacy ofbaseline procalcitonin (PCT) in the detection of bacteremia and in the predictionof outcome in patients with solid tumors and febrile neutropenia.METHODS. PCT levels were determined at baseline and every 48 hours in 104patients undergoing chemotherapy who developed fever (axillary temperature  38 °C on 2 occasions or   38.3 °C in a single record) and neutropenia (absoluteneutrophil count   500 cells/ L).RESULTS. The median baseline PCT values were significantly higher in patientswho had microbiologically documented infections (1.24 ng/mL) compared withpatients who had clinically documented infections (0.27 ng/mL) or fever of unknownorigin (0.21 ng/mL; P   0.01). Accordingly, a PCT cut-off value of 0.5 ng/mLwas reached more frequently in patients who had microbiologically documentedinfections compared with patients who had clinically documented infections orfever of unknown origin (66.7% vs. 13.4%, respectively; P   0.001). Furthermore,this threshold also was associated with an increased likelihood of treatment failure(70.0% vs. 14.9%; P   0.001). All 4 septic patients and all 5 patients who ultimatelydied presented PCT values 5-fold to 10-fold greater than the median values.Clinical evaluation in combination with baseline PCT assessment appeared toimprove clinical risk evaluation alone.CONCLUSIONS. Baseline PCT levels were higher in patients who had febrile neutropeniawith bacteremia compared with patients who had clinical infections orfever of unknown origin. PCT helped to identify patients who had microbiologicinfections and patients who were at high risk of treatment failure, and PCT mayconstitute a complementary tool in the initial assessment of such patie
PB Wiley InterScience
YR 2004
FD 2004-03
LK https://hdl.handle.net/10630/29770
UL https://hdl.handle.net/10630/29770
LA eng
NO Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muñoz A, López-Martín A, Durán I, Robles L, Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004 Jun 1;100(11):2462-9. doi: 10.1002/cncr.20275. PMID: 15160353.
NO Este artículo ha sido publicado en la revista CancerEsta versión tiene Licencia Creative Commons CC-BY-NC-ND  Aportamos pdf que hemos recibido de la revista ante nuestra solicitud de postprint, con permiso de la revista  "Thank you for reaching out. The article can be accessed and downloaded here: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.20275
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026